Clinical Trial Update: Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of XTL 2125 in chronic hepatitis C virus infection patients who are interferon-alp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• XTL 2125

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Chronic Hepatitis C Virus Infection | Phase 1 | Status: WITHDRAWN